The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
Yes Or No? Its Crunch Time For Companies As EMA Meets To Adopt Opinions On Several Marketing Authorization Applications • Source: Shutterstock: Little Pig Studio
Swiss biotech firm Idorsia Pharmaceuticals is set to learn this week whether its insomnia drug daridorexant is on track for EU-wide approval. The drug was authorized as Quviviq in the US in January.
Immunocore could also hear whether its T-cell receptor (TCR) therapy tebentafusp will be recommended for approval for the treatment...
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
<p>Executive Summary</p>
<p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p>
<p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.